Portfolio at a glance
Securities as at March 31, 2023
|
Company |
|
Number of securities |
|
Change since 31.12.2022 |
|
Local currency |
|
Share price |
|
Market value in CHF mn |
|
In % of securities |
|
In % of shareholders' equity |
|
In % of company |
|
Ionis Pharmaceuticals |
|
9 430 000 |
|
(205 000) |
|
USD |
|
35.74 |
|
308.5 |
|
11.9% |
|
13.6% |
|
6.6% |
|
Argenx SE |
|
872 000 |
|
(20 503) |
|
USD |
|
372.58 |
|
297.4 |
|
11.5% |
|
13.1% |
|
1.6% |
|
Vertex Pharmaceuticals |
|
903 000 |
|
(27 523) |
|
USD |
|
315.07 |
|
260.4 |
|
10.0% |
|
11.4% |
|
0.4% |
|
Neurocrine Biosciences |
|
2 590 000 |
|
(140 000) |
|
USD |
|
101.22 |
|
240.0 |
|
9.3% |
|
10.5% |
|
2.7% |
|
Moderna |
|
1 475 000 |
|
(26 951) |
|
USD |
|
153.58 |
|
207.3 |
|
8.0% |
|
9.1% |
|
0.4% |
|
Incyte |
|
2 800 000 |
|
(91 077) |
|
USD |
|
72.27 |
|
185.2 |
|
7.1% |
|
8.1% |
|
1.3% |
|
Intra-Cellular Therapies |
|
3 215 000 |
|
(76 479) |
|
USD |
|
54.15 |
|
159.3 |
|
6.1% |
|
7.0% |
|
3.4% |
|
Alnylam Pharmaceuticals |
|
855 000 |
|
(35 000) |
|
USD |
|
200.32 |
|
156.8 |
|
6.0% |
|
6.9% |
|
0.7% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sage Therapeutics |
|
3 080 000 |
|
129 722 |
|
USD |
|
41.96 |
|
118.3 |
|
4.6% |
|
5.2% |
|
5.2% |
|
Revolution Medicines |
|
4 675 000 |
|
(102 562) |
|
USD |
|
21.66 |
|
92.7 |
|
3.6% |
|
4.1% |
|
4.4% |
|
Agios Pharmaceuticals |
|
4 000 000 |
|
(30 792) |
|
USD |
|
22.97 |
|
84.1 |
|
3.2% |
|
3.7% |
|
7.2% |
|
Macrogenics |
|
9 579 963 |
|
650 000 |
|
USD |
|
7.17 |
|
62.9 |
|
2.4% |
|
2.8% |
|
15.5% |
|
Relay Therapeutics |
|
4 100 000 |
|
(20 720) |
|
USD |
|
16.47 |
|
61.8 |
|
2.4% |
|
2.7% |
|
3.4% |
|
Celldex Therapeutics |
|
1 800 000 |
|
– |
|
USD |
|
35.98 |
|
59.3 |
|
2.3% |
|
2.6% |
|
3.8% |
|
Arvinas |
|
2 120 000 |
|
(16 412) |
|
USD |
|
27.32 |
|
53.0 |
|
2.0% |
|
2.3% |
|
4.0% |
|
Exelixis |
|
2 600 000 |
|
(54 500) |
|
USD |
|
19.41 |
|
46.2 |
|
1.8% |
|
2.0% |
|
0.8% |
|
Crispr Therapeutics |
|
880 000 |
|
(8 605) |
|
USD |
|
45.23 |
|
36.4 |
|
1.4% |
|
1.6% |
|
1.1% |
|
Fate Therapeutics |
|
4 839 779 |
|
– |
|
USD |
|
5.70 |
|
25.3 |
|
1.0% |
|
1.1% |
|
4.9% |
|
Essa Pharma |
|
7 879 583 |
|
– |
|
USD |
|
2.97 |
|
21.4 |
|
0.8% |
|
0.9% |
|
17.9% |
|
Beam Therapeutics |
|
693 121 |
|
– |
|
USD |
|
30.62 |
|
19.4 |
|
0.7% |
|
0.9% |
|
1.0% |
|
Wave Life Sciences |
|
4 494 458 |
|
– |
|
USD |
|
4.33 |
|
17.8 |
|
0.7% |
|
0.8% |
|
4.6% |
|
Rivus Pharmaceuticals 1) |
|
|
|
|
|
USD |
|
|
|
16.0 |
|
0.6% |
|
0.7% |
|
|
|
Mersana Therapeutics |
|
4 189 719 |
|
123 519 |
|
USD |
|
4.11 |
|
15.8 |
|
0.6% |
|
0.7% |
|
3.9% |
|
Scholar Rock Holding |
|
2 132 725 |
|
– |
|
USD |
|
8.00 |
|
15.6 |
|
0.6% |
|
0.7% |
|
4.1% |
|
Generation Bio Co. |
|
3 608 280 |
|
– |
|
USD |
|
4.30 |
|
14.2 |
|
0.5% |
|
0.6% |
|
6.0% |
|
Black Diamond Therapeutics |
|
5 377 839 |
|
– |
|
USD |
|
1.89 |
|
9.3 |
|
0.4% |
|
0.4% |
|
14.7% |
|
Esperion Therapeutics |
|
4 194 064 |
|
– |
|
USD |
|
1.59 |
|
6.1 |
|
0.2% |
|
0.3% |
|
4.7% |
|
Molecular Templates |
|
11 192 003 |
|
– |
|
USD |
|
0.38 |
|
3.9 |
|
0.2% |
|
0.2% |
|
19.9% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Radius Health – Contingent Value Right |
|
8 733 538 |
|
– |
|
USD |
|
0.00 |
|
0.0 |
|
0.0% |
|
0.0% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total securities |
|
|
|
|
|
|
|
|
|
2 594.4 |
|
100.0% |
|
114.0% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other assets |
|
|
|
|
|
|
|
|
|
1.0 |
|
|
|
0.0% |
|
|
|
Other payables |
|
|
|
|
|
|
|
|
|
(319.4) |
|
|
|
(14.0%) |
|
|
|
Net Asset Value |
|
|
|
|
|
|
|
|
|
2 276.0 |
|
|
|
100.0% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1) Unlisted company
Exchange rate as at 31.03.2023: USD/CHF: 0.9153